Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc (MDT) is using an exchange offer to complete the separation of its diabetes business, MiniMed Group, Inc., creating an independent shareholder base for MiniMed. MiniMed positions itself as a global, “full-stack” automated insulin delivery company with CGM, pumps, algorithms, and a unified digital platform across roughly 80 countries.
MiniMed highlights strong recent performance, including $843 million in Q1 FY27 revenue, up 16.6% reported and 15.8% organically, and FY26 revenue above $3.1 billion with 14.2% reported and 8% organic growth. Growth is driven by a portfolio refresh (MiniMed Go, Flex, and planned Fit patch pump), expanding CGM and consumables, and an algorithm platform (SmartGuard today and Vivera fully closed loop targeted for the second half of 2027, subject to FDA clearance).
The business reports high recurring revenue from CGM and consumables, growing pump placements, rising CGM attachment, and broad global commercial infrastructure. The exchange offer itself is made solely by a Form S-4 Prospectus and related SEC documents, which Medtronic urges investors to review before making any decision.
Medtronic plc (symbol: MDT) is the issuer of record for a Form SC TO-I/A filing submitted to the SEC.
Medtronic plc (symbol: MDT) is the issuer of record for a Form 425 filing submitted to the SEC.
Medtronic plc (symbol: MDT) is the issuer of record for a Form 8-K filing submitted to the SEC.
Medtronic plc (MDT) reported that Harry Skip Kiil, its EVP & President Cardiovascular, sold 1,483 Ordinary Shares on September 16, 2026 in an open-market or private transaction at a reported price of $93.65 per share. Following this sale, he directly holds 42,186 Ordinary Shares of Medtronic. The filing indicates no Rule 10b5-1 trading plan was affirmed for this transaction.
Medtronic plc (MDT) describes its strategic rationale for separating MiniMed Group Inc. through an IPO and a follow-on exchange offer. Management characterizes MiniMed as a B2C, lower-margin, higher-R&D-intensity business compared with the rest of Medtronic’s largely B2B portfolio, and states that separation supports increased investment focus on Cardiovascular, MedSurg, and Neuroscience.
MiniMed is portrayed as performing well as an independent company, with strong recent quarterly results and product launches occurring earlier than expected, and Medtronic emphasizes that the current stage is a “second part” of the separation process. The communication also outlines that the exchange offer is being conducted solely pursuant to a Prospectus included in MiniMed’s Form S-4 Registration Statement and Medtronic’s Schedule TO, and stresses that it is informational only and not a recommendation to participate.